DOM-CIPROFLOXACIN TABLET
Land: Kanada
Språk: engelska
Källa: Health Canada
Produktens egenskaper
(SPC)
10-09-2019
Vissa dokument för denna produkt är för närvarande inte tillgängliga, du kan skicka en begäran till vår kundservice och vi kommer att meddela dig så snart vi kan få dem.
Skicka förfrågan.
Skicka förfrågan.
Aktiva substanser:
CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE)
Tillgänglig från:
DOMINION PHARMACAL
ATC-kod:
J01MA02
INN (International namn):
CIPROFLOXACIN
Dos:
100MG
Läkemedelsform:
TABLET
Sammansättning:
CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) 100MG
Administreringssätt:
ORAL
Enheter i paketet:
100
Receptbelagda typ:
Prescription
Terapiområde:
QUINOLONES
Produktsammanfattning:
Active ingredient group (AIG) number: 0123207005; AHFS:
Bemyndigande status:
APPROVED
Tillstånd datum:
2004-03-24
Produktens egenskaper
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
DOM-CIPROFLOXACIN
(Ciprofloxacin Hydrochloride Tablets, USP)
100 mg, 250 mg, 500 mg and 750 mg
ANTIBACTERIAL AGENT
DOMINION PHARMACAL
6111 Royalmount Ave., Suite 100,
Montréal, Quebec
H4P 2T4 DATE OF REVISION: SEPTEMBER 10, 2019
SUBMISSION CONTROL NO.: 229111
_Dom-CIPROFLOXACIN Product Monograph _
_Page 2 of 49_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................ 3
SUMMARY PRODUCT INFORMATION
..................................................................................
3
INDICATIONS AND CLINICAL USE
........................................................................................
3
CONTRAINDICATIONS
.............................................................................................................
6
WARNINGS AND PRECAUTIONS
............................................................................................
6
ADVERSE REACTIONS
............................................................................................................
11
DRUG INTERACTIONS
............................................................................................................
14
DOSAGE AND ADMINISTRATION
........................................................................................
19
OVERDOSAGE
...........................................................................................................................
21
ACTION AND CLINICAL PHARMACOLOGY
......................................................................
21
STORAGE AND STABILITY
....................................................................................................
23
DOSAGE FORMS, COMPOSITION AND PACKAGING
....................................................... 23
PART II: SCIENTIFIC INFORMATION
..................................................................................
25
PHARMACEUTICAL INFORMATION
..........................................................................
Läs hela dokumentet
